Ozempic-maker Novo Nordisk struggles as GLP-1 drugs continue to dominate medicine, culture

0 Views

Thanks! Share it with your friends!

You disliked this video. Thanks for the feedback!

Published Mar 12, 2026

The FDA criticized the maker of Ozempic and Wegovy, Novo Nordisk, for “serious violations” related to the reporting of possible side effects linked to semaglutide, the active ingredient in the drug. NBC News’ Emily Lorsch reports on the GLP-1 drugs.

For more context and news coverage of the most important stories of our day, click here: https://www.nbcnews.com

» Subscribe to NBC News: http://nbcnews.to/SubscribeToNBC
» Subscribe to Here's the Scoop podcast: https://www.nbcnews.com/heres-the-scoop-daily-podcast

Every day, NBC News helps people understand what’s happening and why it matters — through fact-based reporting, meaningful conversations, and powerful stories. From its leading news broadcasts — TODAY, NBC Nightly News, Meet the Press, and Dateline — to NBC News NOW, the 24/7 streaming news channel, plus chart-topping podcasts, the NBC News app, and NBCNews.com, NBC News keeps audiences informed and connected to the stories shaping our world.

Connect with NBC News Online!
NBC News App: https://apps.nbcnews.com/mobile
Breaking News Alerts: https://link.nbcnews.com/join/5cj/breaking-news-signup?cid=sm_npd_nn_yt_bn-clip_190621
Visit NBCNews.Com: http://nbcnews.to/ReadNBC
Find NBC News on Facebook: http://nbcnews.to/LikeNBC
Follow NBC News on Twitter: http://nbcnews.to/FollowNBC
Follow NBC News on Instagram: http://nbcnews.to/InstaNBC

#Ozempic #drug #health

Category: News24
Tags: NBC News NOW, Hallie Jackson NOW

Sign in

Ozempic-maker Novo Nordisk struggles as GLP-1 drugs continue to dominate medicine, culture

Up Next